Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1062 of 6351
-
Radiation boost may stall spread in early metastatic cancers
Disease control OngoingThis phase II trial studies how well systemic therapy with or without local consolidative therapy work in treating patients with solid tumor that has spread to 1 site of other places in the body. Treatment with up-front local consolidative therapy may be better in helping to cont…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
A sharper MRI lens for hidden heart danger
Diagnosis Recruiting nowThis study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time…
Sponsor: Cedars-Sinai Medical Center • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
Hormone boost plus chemo aims to shrink hard-to-treat prostate cancer
Disease control Recruiting nowThe purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
Phase 2 • Sponsor: St Vincent's Hospital, Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a nerve stimulator calm rheumatoid arthritis?
Disease control OngoingLong-term extension of a multi-site, first-in-human study to assess safety and efficacy of an active implantable Vagus Nerve Stimulation (VNS) device in adult patients with active moderate-to-severe rheumatoid arthritis who have had an incomplete response or intolerability to at …
Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New eczema pill shows promise in large trial
Disease control CompletedThe objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Major vaccine study shows meningitis b and pneumonia shots are safe for babies
Vaccine CompletedThe purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recomme…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Aug 22, 2026 00:00 UTC
-
Engineered immune cells injected directly into brain show promise for kids with deadly tumors
Disease control OngoingThis is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4 and CD8 T cells lentivirally transduced to express a HER2-specific chimeric antigen receptor (CAR) and EGFRt, delivered by an indwelling catheter in the tumor resection cavit…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Custom-Made cancer vaccine tested in 25 patients
Vaccine CompletedThe purpose of this study is to determine if it is possible to make and administer safely a 'personalized' vaccine to treat patients that have been diagnosed with advanced cancer and are not candidates for curative therapy.
Phase 1 • Sponsor: Aaron Miller • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
Liver metastases showdown: radiation vs. microwave ablation in new trial
Disease control OngoingThe LAVA-CRLM trial (Local Ablation Versus Ablative radiotherapy in ColoRectal Liver Metastases) is a prospective, randomised, phase 2 study designed to compare local control and safety of microwave ablation (MWA) versus stereotactic body radiotherapy (SBRT)in patients with color…
Phase 2 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can retraining the brain replace the pill? a big trial tests two non-drug paths to pain relief.
Disease control CompletedThe proposed study will fill several critical gaps in evidence that are preventing patients and physicians from making informed decisions about their pain care. This project will provide patients taking opioids and physicians with the specific evidence they need to choose the mos…
Sponsor: Stanford University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough leukemias
Disease control Recruiting nowThis research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid…
Phase 1 • Sponsor: Marlise Luskin, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Targeted radiation may extend life for patients with limited bone metastases
Disease control OngoingBone metastases occur frequently during the evolution of solid tumors, either isolated or associated with visceral metastases. The incidence varies between 20 and 85% depending on the primary cancer. Breast, prostate, and lung cancers are responsible for 70% of bone metastases. C…
Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Aspirin shows promise in blocking ovarian cancer for High-Risk women
Prevention OngoingWhile ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer, and…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
Genetic clues may reveal why some breast cancers resist treatment
Knowledge-focused OngoingThe goal of this research study is to determine if the investigators can predict which participants will respond to endocrine therapy and a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor for metastatic breast cancer and which participants will not. Investigators will use inf…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New combo therapy shows promise for incurable head and neck cancer
Disease control CompletedHead \& neck (H\&N) cancer is the eighth most common cancer in the UK. Advanced H\&N cancer which has come back after treatment or has spread to other parts of the body is incurable and the average life expectancy of these patients is less than a year. New drugs called immune che…
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Glowing dye helps surgeons spot hidden lung cancer
Diagnosis Recruiting nowThis phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen u…
Phase 1/2 • Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
A smarter steroid schedule might tame Chemotherapy's blood sugar spike
Disease control OngoingThis phase II trial studies how well tailored prednisone reduction works in preventing hyperglycemia in participants with B-cell non-Hodgkin lymphoma receiving combination chemotherapy treatment. Drugs used in chemotherapy, such as rituximab, cyclophosphamide, doxorubicin hydroch…
Phase 2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug shows promise for Long-Term ulcerative colitis control
Disease control OngoingThis study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can a One-Two punch of immunotherapy and radiation tame sarcoma before surgery?
Disease control CompletedImmunotherapy + Radiation in Resectable Soft Tissue Sarcoma
Early phase 1 • Sponsor: University of Rochester • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Leukemia drug shows promise in french compassionate use study
Disease control CompletedThe outcome of young adults (18-60 years) with ALL has been dramatically improved by the use of pediatric-inspired trials. About 60% of these young adult patients will be cured at 5 years. In this context, early evaluation of minimal residual disease (MRD) at complete remission h…
Sponsor: Group for Research in Adult Acute Lymphoblastic Leukemia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC